Real world use of long-acting cabotegravir and rilpivirine in a HIV centre in Hong Kong

被引：0

作者：

Chan, M. C. J. ^{[1
]}

Chik, S. H. T. ^{[1
]}

Lamb, S. S. ^{[1
]}

Choi, Y. C. C. ^{[1
]}

Lau, W. T. A. ^{[1
]}

Leung, C. S. E. ^{[1
]}

To, P. Y. L. ^{[1
]}

Lau, P. L. D. ^{[1
]}

Tsang, T. Y. O. ^{[1
]}

机构：

[1] Hosp Author Infect Dis Ctr, Hong Kong, Peoples R China

来源：

HIV MEDICINE | 2023年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R51 [传染病];

学科分类号：

100401 ;

摘要：

814

引用

页码：155 / 156

页数：2

共 50 条

[31] The use and utility of toolkits in supporting cabotegravir plus rilpivirine long-acting implementation in the CARISEL (Cabotegravir And Rilpivirine Implementation Study in European Locations) study [J].

Trehan, Rekha ;

Gutner, Cassidy ;

Okoli, Chinyere ;

Ghosn, Jade ;

Vera, Francisco ;

Florence, Eric ;

Lutz, Thomas ;

van der Valk, Marc ;

Czarnogorski, Maggie .

HIV MEDICINE, 2023, 24 :93-93

[32] Clinical and pharmacological outcomes of real-world use of Long-Acting Cabotegravir and Rilpivirine in France: Efficacy and tolerance during the first 72 weeks [J].

Psomas, C. K. ;

Halfon, P. ;

Salnikova, M. ;

Khiri, H. ;

Tichadelle, F. ;

Allemand, J. ;

Neant, N. ;

Solas, C. ;

Philibert, P. .

HIV MEDICINE, 2023, 24 :81-82

[33] Real-world use of long-acting cabotegravir and rilpivirine: 12-month results of the inJectable Antiretroviral therapy feasiBility Study (JABS) [J].

John, M. ;

Williams, L. ;

Nolan, G. ;

Bonnett, M. ;

Castley, A. ;

Nolan, D. .

HIV MEDICINE, 2024, 25 (08) :935-945

[34] Effect of Obesity on the Exposure of Long-acting Cabotegravir and Rilpivirine: A Modeling Study [J].

Bettonte, Sara ;

Berton, Mattia ;

Stader, Felix ;

Battegay, Manuel ;

Marzolini, Catia .

CLINICAL INFECTIOUS DISEASES, 2024, 79 (02) :477-486

[35] Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine [J].

Daryl Hodge ;

David J. Back ;

Sara Gibbons ;

Saye H. Khoo ;

Catia Marzolini .

Clinical Pharmacokinetics, 2021, 60 :835-853

[36] The future of long-acting cabotegravir plus rilpivirine therapy: deeds and misconceptions [J].

Rusconi, Stefano ;

Santoro, Maria M. ;

Capetti, Amedeo F. ;

Gianotti, Nicola ;

Zazzi, Maurizio .

INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2022, 60 (03)

[37] A cautionary note on entry and exit strategies with long-acting cabotegravir and rilpivirine [J].

Ripamonti, Diego ;

Rusconi, Stefano ;

Zazzi, Maurizio .

AIDS, 2024, 38 (02) :263-265

[38] Long-Acting Cabotegravir for HIV/AIDS Prophylaxis [J].

Engelman, Kathleen D. ;

Engelman, Alan N. .

BIOCHEMISTRY, 2021, 60 (22) :1731-1740

[39] Rilpivirine and cabotegravir trough concentrations in people with HIV on long-term treatment with long-acting injectable antiretrovirals [J].

Cossu, Maria Vittoria ;

Cattaneo, Dario ;

Moschese, Davide ;

Giacomelli, Andrea ;

Soloperto, Sara ;

D'Avolio, Antonio ;

Antinori, Spinello ;

Gori, Andrea ;

Rizzardini, Giuliano ;

Gervasoni, Cristina .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 79 (05) :1126-1132

[40] Real life data on clinical and laboratory outcomes of long acting cabotegravir and rilpivirine in people with HIV [J].

Mazzitelli, M. ;

Agostini, E. ;

Sasset, L. ;

Leoni, D. ;

Gardin, S. ;

Presa, N. ;

Putaggio, C. ;

Bragato, B. ;

Parisi, S. ;

Cattelan, A. .

HIV MEDICINE, 2023, 24 :152-153

← 1 2 3 4 5 →